Neurochemical biomarkers in Alzheimer’s disease and related disorders

Por Bibl, Mirko, Esselmann, Hermann, Wiltfang, Jens
Publicado em 2012

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Por Bibl, Mirko, Gallus, Marion, Welge, Volker, Esselmann, Hermann, Wolf, Stefanie, Rüther, Eckart, Wiltfang, Jens
Publicado em 2012

Correction to: Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Por Bibl, Mirko, Gallus, Marion, Welge, Volker, Esselmann, Hermann, Wolf, Stefanie, Rüther, Eckart, Wiltfang, Jens
Publicado no J Neural Transm (Vienna) (2018)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia

Por Bibl, Mirko, Esselmann, Hermann, Lewczuk, Piotr, Trenkwalder, Claudia, Otto, Markus, Kornhuber, Johannes, Wiltfang, Jens, Mollenhauer, Brit
Publicado em 2010

Plasma Amyloid‐BetaPeptides in Acute Cerebral Ischemia: A Pilot Study

Por Bibl, Mirko, Welge, Volker, Schmidt, Holger, Esselmann, Hermann, Mollenhauer, Brit, Lewczuk, Piotr, Otto, Markus, Kornhuber, Johannes, Wiltfang, Jens
Publicado no J Clin Lab Anal (2012)

CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

Por Bibl, Mirko, Mollenhauer, Brit, Esselmann, Hermann, Lewczuk, Piotr, Klafki, Hans-Wolfgang, Sparbier, Katrin, Smirnov, Alexandr, Cepek, Lukas, Trenkwalder, Claudia, Rüther, Eckart, Kornhuber, Johannes, Otto, Markus, Wiltfang, Jens
Publicado no Brain (2006)